GlassScriptPhysician profile
Jisoon Hwang
NPI 1407108319
$4,298.15
in general payments reported to CMS, 2019-2025
26 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $593 · 2022: $692 · 2023: $1,523 · 2024: $1,079 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,012.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $743.87 | 2023-2024 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $332.55 | 2021-2023 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $284.37 | 2021-2024 | Fasenra |
| Abbvie INC. | $234.76 | 2023 | |
| Emd Serono, INC. | $228.38 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $226.44 | 2024 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $223.76 | 2024 | |
| Novo Nordisk INC | $214.77 | 2021-2022 | |
| Boston Scientific Corporation | $138.43 | 2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Krystexxa |
| Ars Pharmaceuticals Operations, INC. | $121.69 | 2025 | Neffy |
| Aimmune Therapeutics, INC. | $119.52 | 2024 | |
| Novartis Pharmaceuticals Corporation | $118.42 | 2023 | |
| Amarin Pharma, INC. | $117.34 | 2023 | |
| Jazz Pharmaceuticals INC. | $115.61 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $114.55 | 2022 | |
| Biogen, INC. | $105.12 | 2022 | |
| Axsome Therapeutics, INC. | $104.58 | 2025 | Auvelity |
| Corcept Therapeutics | $102.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $101.01 | 2023 | Quviviq |
| Celgene Corporation | $96.81 | 2021 | |
| Insmed, INC. | $93.46 | 2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $89.78 | 2024 | |
| Sage Therapeutics, LLC | $76.80 | 2025 | |
| Recordati_rare_diseases_inc. | $54.96 | 2024 | Sylvant |
| Pfizer INC. | $14.07 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jisoon Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.